EVALUATION OF PREVALENCE OF COMPLICATIONS OF MEASLES

http://dx.doi.org/10.31703/gpsr.2017(II-I).04      10.31703/gpsr.2017(II-I).04      Published : Dec 1
Authored by : HinaShoukat , FahadPervaiz , SobiaNoreen , AyeshaKhadim , MairaLatif

04 Pages : 34-41

References

  • American Academy of Pediatrics, 2009:444-55. Isabel Peña-Rey1,2, *, María Victoria Martínez de Aragón1,2, Odorina Tello Anchuela1,2, Josefa Masa1, Enrique Alcalde Cabero1, María Teresa Castellanos Ruiz1 and Regional Coordinators of the MeaslesElimination Plan#1Servicio de Vigilancia Epidemiológica, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, 28028Madrid, Spain2CIBER Epidemiologia y Salud Publica (CIBERESP), Spain
  • American Academy of Pediatrics. Measles. In: Pickering L, Baker C, Kimberlin D, Long S, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL:
  • Bernstein, D. I., Schiff, G.M., Measles. In: Infectious Diseases, Gorbach SL, Bartlett JG, Blacklow NR (Eds), WB Saunders, Philadelphia 1998. p.1296.
  • Cherry, J. D., Measles, virus. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, et al (Eds), Saunders, Philadelphia 2009. p.2427.
  • Epidemology, & Prevention. of vaccine preventable diseases, The Pink Book:Course Text Book-2th edition 2nd printing (may 2012) )Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis 2004; 189 Suppl 1: S4.BABBOTT FL Jr, GORDON JE. Modern measles. Am J Med Sci 1954; 228:334.
  • Hopkins Bloomberg School of Public Health, Baltimore, Maryland
  • Markowitz, L. E., Preblud, S. R., Fine, P. E., & Orenstein, W. A. (1990). Duration of live measles vaccine-induced immunity.Pediatr Infect Dis J. Feb 9(2),101-[Medline]
  • mumps, & rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998;47(No. RR-8):1-57. (http://www.who.int/vaccines- documents/) http://emedicine.medscape.com/a rticle/966220-medication
  • Robert, T., Perry, 1., & Neal, A. Halsey2 1National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia; 2Department of International Health, Johns
  • Schneider-Schaulies, S., Schneider-Schaulies, J., & Measles. virus-induced immunosuppression. Curr Top MicrobiolImmunol. 2009; 330:243- 69. [Medline].
  • Stephen, J., McPhee, Maxine, A., & Papadakis. (2011). Current Medical Diagnosis and Therapeutics,50th edition, McGraw- hillCompanies,USA.

References

  • American Academy of Pediatrics, 2009:444-55. Isabel Peña-Rey1,2, *, María Victoria Martínez de Aragón1,2, Odorina Tello Anchuela1,2, Josefa Masa1, Enrique Alcalde Cabero1, María Teresa Castellanos Ruiz1 and Regional Coordinators of the MeaslesElimination Plan#1Servicio de Vigilancia Epidemiológica, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, 28028Madrid, Spain2CIBER Epidemiologia y Salud Publica (CIBERESP), Spain
  • American Academy of Pediatrics. Measles. In: Pickering L, Baker C, Kimberlin D, Long S, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL:
  • Bernstein, D. I., Schiff, G.M., Measles. In: Infectious Diseases, Gorbach SL, Bartlett JG, Blacklow NR (Eds), WB Saunders, Philadelphia 1998. p.1296.
  • Cherry, J. D., Measles, virus. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, et al (Eds), Saunders, Philadelphia 2009. p.2427.
  • Epidemology, & Prevention. of vaccine preventable diseases, The Pink Book:Course Text Book-2th edition 2nd printing (may 2012) )Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis 2004; 189 Suppl 1: S4.BABBOTT FL Jr, GORDON JE. Modern measles. Am J Med Sci 1954; 228:334.
  • Hopkins Bloomberg School of Public Health, Baltimore, Maryland
  • Markowitz, L. E., Preblud, S. R., Fine, P. E., & Orenstein, W. A. (1990). Duration of live measles vaccine-induced immunity.Pediatr Infect Dis J. Feb 9(2),101-[Medline]
  • mumps, & rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998;47(No. RR-8):1-57. (http://www.who.int/vaccines- documents/) http://emedicine.medscape.com/a rticle/966220-medication
  • Robert, T., Perry, 1., & Neal, A. Halsey2 1National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia; 2Department of International Health, Johns
  • Schneider-Schaulies, S., Schneider-Schaulies, J., & Measles. virus-induced immunosuppression. Curr Top MicrobiolImmunol. 2009; 330:243- 69. [Medline].
  • Stephen, J., McPhee, Maxine, A., & Papadakis. (2011). Current Medical Diagnosis and Therapeutics,50th edition, McGraw- hillCompanies,USA.

Cite this article

APA

CHICAGO

    CHICAGO : Shoukat, Hina, Fahad Pervaiz, and Sobia Noreen. 2017. "Evaluation of Prevalence of Complications of Measles." Global Pharmaceutical Sciences Review, II (I): 34-41 doi: 10.31703/gpsr.2017(II-I).04

HARVARD

    HARVARD : SHOUKAT, H., PERVAIZ, F. & NOREEN, S. 2017. Evaluation of Prevalence of Complications of Measles. Global Pharmaceutical Sciences Review, II, 34-41.

MHRA

    MHRA : Shoukat, Hina, Fahad Pervaiz, and Sobia Noreen. 2017. "Evaluation of Prevalence of Complications of Measles." Global Pharmaceutical Sciences Review, II: 34-41

MLA

    MLA : Shoukat, Hina, Fahad Pervaiz, and Sobia Noreen. "Evaluation of Prevalence of Complications of Measles." Global Pharmaceutical Sciences Review, II.I (2017): 34-41 Print.

OXFORD

    OXFORD : Shoukat, Hina, Pervaiz, Fahad, and Noreen, Sobia (2017), "Evaluation of Prevalence of Complications of Measles", Global Pharmaceutical Sciences Review, II (I), 34-41

TURABIAN

    TURABIAN : Shoukat, Hina, Fahad Pervaiz, and Sobia Noreen. "Evaluation of Prevalence of Complications of Measles." Global Pharmaceutical Sciences Review II, no. I (2017): 34-41. https://doi.org/10.31703/gpsr.2017(II-I).04